Dermatol Ther. 2022 May 14:e15583. doi: 10.1111/dth.15583. Online ahead of print.
ABSTRACT
BACKGROUND: There is limited evidence about the real-world survival of apremilast in patients with psoriasis, especially over the long term.
OBJECTIVES: To evaluate the long-term survival of apremilast and its predictive factors when used to treat psoriasis.
METHODS: A retrospective hospital-based study, including data collected from 104 patients. Survival curves were estimated using the Kaplan-Meier estimator. Proportional hazard Cox regression models were used for multivariate analysis.
RESULTS: The average duration of the treatment before discontinuation was 28.82 months (95% CI, 22.08-35.57 months) and the median was 12 months (95% CI, 2.68-21.31 months). The retention rates were 51% (1 year), and 33% (5 years). The survival study revealed statistically significant differences between patients with PASI<10 and those in the PASI≥10 group (log-rank test, p<0.001). The five-year prevalences were 64% for patients with a PASI of <10 and 5% for those with an index ≥10. In the PASI<10 patient group the retention rates were 77% (1 year) and 64% (5 years). Furthermore, 66% of patients who continued apremilast treatment for more than 2 years were receiving off-label doses (30 mg/day).
CONCLUSIONS: Apremilast may be a suitable and efficient alternative for the treatment of psoriasis patients in the PASI<10 group. This article is protected by copyright. All rights reserved.
PMID:35567525 | DOI:10.1111/dth.15583